For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The LANCE® Ultra Human MMP-12 Detection Kit is designed for detection and quantitation of Matrix metalloproteinase 12 in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Human matrix metalloproteinase 12 (MMP12, macrophage elastase ), a member of the matrix metalloproteinase family, is an enzyme composed of a pro domain, a catalytic domain containing the zinc-binding site, and a C-terminal hemopexin-like domain. MMP12 can degrade soluble and insoluble elastin and type IV collagen, fibronectin, laminin, vitronectin, proteoglycans, chondroitin sulfate, myelin basic protein, alpha 1-antitrypsin, and plasminogen. Like other MMPs, MMP12 is involved in the degradation of basement membranes and thus cancer development. This kit has been designed for the detection of Human MMP12 in cell culture supernatants.
| Assay Target | MMP12 |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Time-Resolved Fluorescence (TRF), TR-FRET |
| Experimental Type | In vitro |
| Product Brand Name | LANCE Ultra |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Oncology |
| Unit Size | 500 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
